Dr. Peter Sennhenn

Inhaber, CEO, transMedChem

München, Deutschland

Fähigkeiten und Kenntnisse

Medicinal Chemistry
Drug Discovery
Medicinal Chemistry Consulting
Translational Research
Preclinical Research and Development
HTS Analysis and Evaluation
Hit Selection
Lead Identification
Multidimensional Lead Optimization
Candidate Selection
CMC
Compound Library Design
Structure-Based Drug Design
Fragment-Based Drug Discovery
Modeling
Organic Synthesis
Project Management Services
Target Identification
Oncology
Virology
Immunology
Kinases
Proteases
Protein-Protein Interaction
Epigenetic Targets
Lab Infrastructure Design & Setup
Outsourcing
Research Proposal Review
Due Diligence
IP Strategy
Antibiotics

Werdegang

Berufserfahrung von Peter Sennhenn

  • Bis heute 12 Jahre, seit Juni 2012

    CEO

    transMedChem

  • 3 Jahre und 8 Monate, Nov. 2013 - Juni 2017

    VP Medicinal Chemistry

    Bioversys AG

  • 2008 - 2012

    Director Medicinal Chemistry

    Proteros

  • 2005 - 2008

    Director Medicinal Chemistry

    GPC Biotech

  • 2001 - 2005

    Group Leader Medicinal Chemistry

    Boehringer Ingelheim Austria

  • 1996 - 2000

    Lab Head Medicinal Chemistry

    Boehringer Ingelheim Germany

Ausbildung von Peter Sennhenn

  • 1995 - 1996

    The Scripps Research Institute, CA

    Sharpless Labs

  • 1991 - 1991

    University of Cambridge, UK

    A. B Holmes Group

  • 1984 - 1995

    University of Heidelberg, D

    AK Prof. Helmchen

Sprachen

  • Englisch

    Fließend

  • Deutsch

    Muttersprache

  • Französisch

    Grundlagen

  • Spanisch

    Grundlagen

Interessen

Golf
Team Handball
Design
Photography
Mountain biking

21 Mio. XING Mitglieder, von A bis Z